The latest: The Capital Group Companies, Inc., a U.S.-based fund disclosed it purchased 1.285 million shares in Hutchmed (China) Ltd. (HCM.US; 0013.HK) for HK$22.14 million ($2.84 million), raising its stake from 8.93% to 9.08%, according to a Hong Kong Stock Exchange filing.

Looking up: Although Hutchmed’s U.S.-listed shares are at risk of delisting, its Hong Kong shares are still being purchased by a U.S.-based fund, reflecting this shareholder’s confidence in the company’s prospects.

Take Note: The average price per share for The Capital Group’s increased stake in Hutchmed is HK$17.236. Based on the stock’s closing price of HK$15.7 on Tuesday, this means the shareholder has recorded a 9% book loss.

Digging Deeper: Founded in 2000, Hutchmed is a biopharmaceutical company owned by Hong Kong billionaire Li Ka-shing. It is in the commercialization stage of developing innovative cancer drugs. The company has undergone some changes this year, with the retirement of its CEO of 22 years, Christian Hogg, in March, and it was placed on a conclusive list of companies that could face the threat of delisting under the Foreign Company Accountability Act by the U.S. Securities and Exchange Commission (SEC). The company responded that it would continue to evaluate all options for maintaining its U.S. listing, including the appointment of an auditor outside of China and how it can meet the requirements of the Act.

Market Reaction: Hutchmed’s Hong Kong shares opened 2.3% higher on Wednesday morning, but the gains later slightly narrowed to 1.9% and closed at HK$16 at the midday break. It now trades at the lower end of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Lanvin revenue grows 1% in 2023

NEWS WRAP: Lanvin business stagnates in 2023

The unit of Chinese conglomerate Fosun reported its revenue rose just 1% last year as the global luxury goods market stalled    By Teri Yu Luxury fashion brand operator Lanvin…
Venus Medtech shares remain suspended

Venus Medtech still seeking cure for governance problems

The transcatheter maker’s shares were suspended last November, and it must still meet several conditions from the Hong Kong Stock Exchange before trading can resume Key Takeways: Venus Medtech disclosed…